Intravesical bacille calmette-guérin versus mitomycin c in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression

Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials

2002 • 1,248 citations

MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY

2000 • 1,225 citations

Superficial Bladder Cancer: Progression and Recurrence

1983 • 947 citations

Intravesical Bacillus Calmette-Guerin Versus Mitomycin C For Superficial Bladder Cancer: A Formal Meta-Analysis of Comparative Studies on Recurrence and Toxicity

2003 • 524 citations

Guidelines on Bladder Cancer

2002 • 471 citations

MULTIVARIATE ANALYSIS OF THE PROGNOSTIC FACTORS OF PRIMARY SUPERFICIAL BLADDER CANCER

2000 • 432 citations

A systematic review of intravesical bacillus Calmette‐Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer

2001 • 280 citations

A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer.

1996 • 273 citations

5-YEAR FOLLOWUP OF A RANDOMIZED PROSPECTIVE STUDY COMPARING MITOMYCIN C AND BACILLUS CALMETTE-GUERIN IN PATIENTS WITH SUPERFICIAL BLADDER CARCINOMA

1999 • 252 citations

A Combined Analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council Randomized Clinical Trials for the Prophylactic Treatment of Stage TaT1 Bladder Cancer

1996 • 238 citations

Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association.

1999 • 217 citations

TUMOR PROGRESSION AND SURVIVAL OF PATIENTS WITH HIGH GRADE, NONINVASIVE PAPILLARY (TaG3) BLADDER TUMORS: 15-YEAR OUTCOME

2000 • 214 citations

A Randomized Multicenter Trial of Adjuvant Therapy in Superficial Bladder Cancer: Transurethral Resection Only Versus Transurethral Resection Plus Mitomycin C Versus Transurethral Resection Plus Bacillus Calmette-Guerin

1996 • 197 citations

BLADDER CANCER CLINICAL GUIDELINES PANEL SUMMARY REPORT ON THE MANAGEMENT OF NONMUSCLE INVASIVE BLADDER CANCER (STAGES Ta, T1 AND TIS)

1999 • 189 citations

Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study

1995 • 136 citations

Original Articles: Bladder Cancer: A Randomized Study of Intravesical Mitomycin C, Bacillus Calmette-Guerin Tice and Bacillus Calmette-Guerin RIVM Treatment in pTa-pT1 Papillary Carcinoma and Carcinoma in Situ of the Bladder

1995 • 123 citations

Comparison of Different Schedules of Cytostatic Intravesical Instillations in Patients with Superficial Bladder Carcinoma: Final Evaluation of a Prospective Multicenter Study with 419 Patients

1990 • 97 citations

Superficial bladder cancer

2002 • 94 citations

Original Articles

1995 • 92 citations

The T1 bladder tumor.

1990 • 76 citations

Immunotherapy in Urological Tumors.

2019 • 34 citations

Bacillus Calmette-Guérin versus mitomycin intravesical therapy in superficial bladder cancer: Results of randomized trial after 21 months of follow-up

1992 • 14 citations

Bacillus Calmette-Guérin versus mitomycin intravesical therapy in superficial bladder cancer

1992 • 13 citations

[Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75 mg of Pasteur strain BCG].

1998 • 9 citations

Cited By (0)

No citing papers found in database